Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
High-resolution analytical platforms, proteomics-driven workflows, and expanding CRO outsourcing reshape strategic priorities ...
Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to ...
Large language models (LLMs) can be broadly applied across multiple key stages in drug development: (1) Target identification and drug screening. Llama-Gram, GPCR LLM, and ProtChat systems effectively ...
AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...
GUEST COMMENTARY—For millions of patients, the slow pace of drug discovery means years – sometimes decades – without effective treatments. Many diseases remain untreatable, not because they are rare ...
Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.
Demonstrates how dual-purpose therapeutic targets may address both hepatocellular carcinoma progression and cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results